Exact Sciences Corp. [EXAS] stock is trading at $71.34, down -2.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EXAS shares have gain 1.58% over the last week, with a monthly amount glided 16.80%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Exact Sciences Corp. [NASDAQ: EXAS] stock has seen the most recent analyst activity on January 02, 2024, when The Benchmark Company upgraded its rating to a Buy but kept the price target unchanged to $91 for it. Previously, Guggenheim started tracking the stock with Buy rating on December 14, 2023, and set its price target to $90. On December 13, 2023, Wolfe Research initiated with a Outperform rating and assigned a price target of $95 on the stock. Piper Sandler upgraded its rating to a Overweight but stick to its price target of $90 on October 10, 2023. Bernstein initiated its recommendation with a Outperform and recommended $83 as its price target on September 28, 2023. The Benchmark Company downgraded its rating to Hold for this stock on August 02, 2023. In a note dated May 10, 2023, Craig Hallum upgraded an Buy rating on this stock and boosted its target price from $55 to $85.
Exact Sciences Corp. [EXAS] stock has fluctuated between $56.05 and $100.77 over the past year. Currently, Wall Street analysts expect the stock to reach $106.29 within the next 12 months. Exact Sciences Corp. [NASDAQ: EXAS] shares were valued at $71.34 at the most recent close of the market. An investor can expect a potential return of 48.99% based on the average EXAS price forecast.
Analyzing the EXAS fundamentals
Exact Sciences Corp. [NASDAQ:EXAS] reported sales of 2.50B for the trailing twelve months, which represents a growth of 16.98%. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.08%, and Net Profit Margin reading is -0.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.07 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 70.38 points at the first support level, and at 69.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 72.70, and for the 2nd resistance point, it is at 74.05.
Ratios To Look Out For
For context, Exact Sciences Corp.’s Current Ratio is 2.32. As well, the Quick Ratio is 2.07, while the Cash Ratio is 1.18. Considering the valuation of this stock, the price to sales ratio is 5.18, the price to book ratio is 4.11.
Transactions by insiders
Recent insider trading involved Baranick Brian, EVP, GM., Precision Oncology, that happened on Apr 02 ’24 when 924.0 shares were sold. EVP, Human Resources, Condella Sarah completed a deal on Apr 01 ’24 to sell 2000.0 shares. Meanwhile, EVP, Human Resources Condella Sarah sold 2000.0 shares on Mar 28 ’24.
